<DOC>
	<DOCNO>NCT02752074</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability combine pembrolizumab epacadostat placebo subject unresectable metastatic melanoma</brief_summary>
	<brief_title>A Phase 3 Study Pembrolizumab + Epacadostat Placebo Subjects With Unresectable Metastatic Melanoma ( Keynote-252 / ECHO-301 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Have histologically cytologically confirm melanoma Have unresectable Stage III Stage IV melanoma , per AJCC stag system amenable local therapy A minimum 1 measurable lesion CT MRI Provide baseline tumor biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Has receive prior systemic treatment unresectable metastatic melanoma ( except BRAF direct therapy ) Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , IDO1 inhibitor antibody drug specifically target checkpoint pathway antiCTLA4 permit adjuvant setting Has receive prior adjuvant therapy , monoclonal antibody investigational agent device within 4 week 5 halflives ( whichever longer ) Has active infection require systemic therapy Has know history human immunodeficiency virus ( HIV ) ( HIV 1/2 antibody ) Has know history positive Hepatitis B Hepatitis C Is pregnant breastfeed expect conceive father child within project duration study , start screen visit 120 day last dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
</DOC>